The aim of the present study was to evaluate the association between statin use and the risk of agerelated macular degeneration (AMD). A systematic search of the PubMed, EMBASE and ISI web of science databases was used to identify eligible published literatures without language restrictions up to April 2015. Summary relative ratios (RRs) and 95% CIs were estimated using a fixed-effect or randomeffects model. A total of 14 studies met the inclusion criteria and were included in this meta-analysis. , presenting a growing public health problem among the aging population 4 . Although the pathogenesis of AMD remains elusive, inflammation and oxidative damage have also been implicated as playing a crucial role in this disease 5 . Epidemiological studies have demonstrated that AMD and cardiovascular disease share many risk factors, such as smoking, elevated serum cholesterol, atherosclerosis and hypertension 6, 7 . Thus, the drugs lowering the risk of cardiovascular disease might also confer a protective effect for AMD. As hydroxymethylglutarylcoenzyme A (HMGCo-A) reductase inhibitors, statins reduce low-density lipoprotein (LDL) levels and exert anti-inflammatory effects, in addition to modifying dyslipidemia, both of which are relevant in the development of AMD, indicating that statin use might play a potential role in reducing the risk of disease 8, 9 . Recently, many studies have investigated the relationship between statin use and the risk of AMD; however, the results of these studies have been inconsistent 10, 11 . In addition, the pathological hallmarks of the disease might differ during early and late AMD; and whether the effect of statin use is controversial during different stages remain unclear 12 . Therefore, we conducted a meta-analysis to pool the results of all available association studies between statin use and the risk of AMD. Furthermore, stratified analyses were also conducted to explore associations with differentiation in AMD subtype.
1
. The common features of early AMD include the the presence of drusen and pigmentary abnormalities in the retinal pigment epithelium (RPE); and late AMD is manifested through geographic atrophy or the development of neovascularization 2 . Approximately 8.7% of the world population suffers from AMD, and the projected number of people with this disease is approximately 196 million individuals in 2020, increasing to 288 million in 2040 3 , presenting a growing public health problem among the aging population 4 . Although the pathogenesis of AMD remains elusive, inflammation and oxidative damage have also been implicated as playing a crucial role in this disease 5 . Epidemiological studies have demonstrated that AMD and cardiovascular disease share many risk factors, such as smoking, elevated serum cholesterol, atherosclerosis and hypertension 6, 7 . Thus, the drugs lowering the risk of cardiovascular disease might also confer a protective effect for AMD. As hydroxymethylglutarylcoenzyme A (HMGCo-A) reductase inhibitors, statins reduce low-density lipoprotein (LDL) levels and exert anti-inflammatory effects, in addition to modifying dyslipidemia, both of which are relevant in the development of AMD, indicating that statin use might play a potential role in reducing the risk of disease 8, 9 . Recently, many studies have investigated the relationship between statin use and the risk of AMD; however, the results of these studies have been inconsistent 10, 11 . In addition, the pathological hallmarks of the disease might differ during early and late AMD; and whether the effect of statin use is controversial during different stages remain unclear 12 . Therefore, we conducted a meta-analysis to pool the results of all available association studies between statin use and the risk of AMD. Furthermore, stratified analyses were also conducted to explore associations with differentiation in AMD subtype.
Statin use and AMD. The relationship between statin use and risk of AMD was evaluated in fifteen studies, comprising 235,021 participants (Table 1) . Among these studies, twelve studies showed no association between statin use and AMD, one study showed a significantly reduced risk of this disease while one study showed a significantly increased risk of the AMD. The pooled results revealed that users of stain compared with non-users conferred a summarized RR of 0.95 (95% CI, 0.74-1.15; Fig. 2 ), using the random effect model. Significant heterogeneity was detected across these studies (I 2 = 91.7%; P < 0.001). When excluding cross-sectional studies in the secondary analysis, this association was not appreciably altered (RR, 0.94; 95% CI, 0.72-1.16). The results of stratified analyses showed significant inconsistency in the direction of effect when studies were grouped according to early and late stages and the I 2 for statistics decreased from 91.7% to 0%. However, the other characteristics of participants shared consistency in the direction of effect. In addition, the pooled RRs remained stable after removing each study one at a time. We did not observe any evidence for the presence of publication bias in the eligible studies (Begg's test P = 0.57; Egger's test P = 0.20).
Statin use and early AMD. Seven studies reported data on the association between stain use and early AMD, with a total of 37,308 participants. Although most of these studies showed a protective tendency, none of these studies showed any significant association between statin use and early AMD. When the results of these studies were pooled into the meta-analysis, the use of statins was significantly associated with lower risk for early AMD (RR, 0.83; 95% CI, 0.66-0.99; I 2 = 0%, P = 0.33; Fig. 3 ). The results of the stratified analysis based on cohort study showed that the association between statin use and early AMD remained robust (RR, 0.77; 95% CI, 0.56-0.97; Table 2 ). In addition, the stratified analysis according to early AMD subtypes was performed and the results revealed that individuals with statin use had approximately 45% and 16% lower risks of soft indistinct drusen (RR, 0.55; 95% CI, 0.29-0.81) and large drusen (RR, 0.84; 95% CI, 0.68-0.99), respectively. The sensitivity analysis showed that the significant relationships among the pooled RRs remained stable between stain use and early AMD. No evidence for the presence of publication bias was detected (P > 0.05).
Statin use and late AMD. We subsequently evaluated the effect of statins on the risk for late AMD in eight studies, with a total of 22,973 participants. The present results showed that no significant associations of statin use with the risk for late stage AMD were observed (RR, 0.92; 95% CI, 0.77-1.07; I 2 = 0%; P = 0.63; Fig. 4 ). The pooled RR of late AMD based on cohort studies could did not substantially differ (RR, 0.95; 95% CI, 0.68-1.22). However, stratified analyses showed that the use of stains conferred a significant decrease for CNV risk (RR, 0.90; 95% CI, 0.80-0.99), whereas no effect was observed for GA (RR, 1.16; 95% CI, 0.77-1.56). For CNV, the results of stratified analysis based on cohort studies found that statin use had a protective tendency for the risk of this disease, but did not reach statistic significant (RR, 0.82; 95% CI, 0.41-1.23). Moreover, no publication bias was detected (P > 0.05).
Discussion
The results from this meta-analysis showed that statin use was significantly associated with lower risk for early AMD compared with non-users. Moreover, in contrast with the absent association between statins and GA, we observed a significant association of statin use with exudative AMD, indicating that statins might have a protective role in the prevention of early AMD and exudative AMD. AMD and cardiovascular disease share many common pathophysiological mechanisms, and low-density lipoprotein cholesterol (LDL) has been detected in the retinal pigment epithelium (RPE) and Bruch's membrane, for which deposition is thought with be analogous to that in the arterial intima in atherosclerosis 25 . The previous study identified that inflammation through the production of mature mediators could initiate inflammasome formation in the RPE, thereby mediating cell death, and ultimately leading to epithelium degeneration 26 . As the first-line drug therapy for the prevention of cardiovascular disease, statins are a class of medications that reduce serum LDL cholesterol 25, 27 . Increasing laboratory-based studies have demonstrated that statins exert anti-inflammatory, antioxidant, and pleiotropic effects that might reduce the risk of AMD. Recently, multiple studies have been conducted to evaluate the effects of statin use and AMD development or progression; however, the results from the published medical literature relating to the association of statin intake and AMD remained controversial. A previous meta-analysis including seven studies was performed in 2007, which showed no association between statin and the risk of this disease, consistent with previous results
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; however, the most of these studies were absent of AMD classification and could not elaborate the relationship between statin use and the risk of AMD subtypes. Due to different pathogenic mechanisms, the potential effects of statin intake might differ between early and late AMD 29 . This hypothesis was also supported through the finding of the stratified analysis showing that statin use had a more protective effect during early AMD compared with late stage AMD. In addition, inconsistent with the source of heterogeneity in the previous meta-analysis entirely ascribed to the study of McGwin et al., there was no evidence of significant heterogeneity in the present study after performing a stratified analysis based on AMD subtypes, indicating that the different clinical stages of this disease might be the main source of heterogeneity. Therefore, it is necessary to evaluate the relationships between statin use and different stages of AMD. In the present study, statin use could significantly reduce the early AMD risk by approximately 13%, primarily contributing to the lipid-lowering effects of this drug. Curcio et al. showed that statin-mediated reduction in serum LDL cholesterol levels might decrease LDL cholesterol to deposit in drusen 30 . In addition to lipid-lowering effects, statins also show anti-inflammatory through the suppression of the activation of the inflammatory pathway in macrophages. Furthermore, statins decrease the plasma concentrations of C-reactive protein (CRP) through the reduction of the number of inflammatory cells and inflammatory cell functions 31, 32 . As an inflammatory marker, higher concentrations of CRP could reduce the deactivation of the complement cascade, resulting in alterations in the RPE and damage to the underlying Bruch' s membrane; and a cascade of decreased levels and drusen accumulation 33 . This result was consistent with Seddon et al., showing that elevated CRP levels were independent risk factors in the pathogenesis of AMD 34 . Therefore, statin use might play a more prominent role in drusen initiation, which could retard the onset and progression of early stage AMD.
In contrast with the absent effect of statins for GA, the results revealed a significant risk reduction for exudative AMD in statin users, likely reflecting the anti-inflammatory effects of statins. Chronic inflammation could lead to endothelial dysfunction and macrophage activations, and activated macrophages secrete chemokines and vascular endothelial growth factor, causing further cellular damage, Bruch's membrane degradation and choroidal neovascularization, which have been implicated in the development of this disease 25, 35 . However, macrophages and other leukocytes might be inefficiently involved in the formation of GA, which is primarily caused by the loss of retinal pigment epithelium and photoreceptors 36 . Statins remit chronic inflammation after relieving the interactions between macrophages, modified lipoproteins, and some elements of the retinal arterial wall, which might partly explain why statin significantly reduces the risk of CNV rather than GA.
Some potential limitations of the present study merit consideration in interpreting the findings. First, although these study designs might be inherently biased through various factors due to the observational nature of the studies included, the combined sample size was relatively large, potentially adding to the strength of this analysis. Second, although the present results showed that statin use could significantly reduce the risk of CNV, the results based on cohort studies found that statin use only had a protective tendency for this AMD subtype, indicating that such association still needed to be investigated to confirm. Third, although these results were based on adjusted estimates, these studies differed in adjusted covariates, and a more precise analysis should be conducted when individual data are available, thereby facilitating adjustment through more potential confounding factors. Forth, the definition of AMD varied between studies and various grading systems have been used in different countries and during different periods in which the studies were performed. Although the RR of AMD associated with statin use did not substantially differ after stratified analysis, the different criteria of this disease might also affect the present results. Finally, the potential publication bias was also a concern. Although we did not observe apparent publication bias through statistical tests, it was still difficult to completely rule out this problem because there was no an abundant amount of studies to adequately detect biases.
In conclusion, the meta-analysis demonstrated a protective association of statin use and early AMD, regardless of soft indistinct drusen or large drusen. Moreover, compared with the absent effect of statins and GA, statin use might reduce the risk of exudative AMD. To date, the association of statin use with subtypes of AMD still required to be confirmed, especially for CNV. Moreover, there is insufficient evidence from RCTs suggesting that statin use might delay the onset of AMD, and the data from RCTs could provide insight into the role for statins in AMD prevention. Therefore, further well-designed large prospective cohort studies and RCTs are warranted before definitive conclusions can be drawn regarding the potential effects of statins on AMD prevention.
Methods
Search strategy. A computerized literature search of MEDLINE, EMBASE, and ISI web of science databases through April 2015 was conducted to identify all relevant articles involving the association of stain use with AMD, using the search terms: ("antilipidemic agents" or "anticholesteremic agents" or "hydroxymethylglutaryl-CoA reductase inhibitors" or "statin") and ("AMD" or "age-related maculopathy" or "neovascular AMD" or "exudative AMD" or "choroidal neovascularization (CNV)" or "geographic atrophy (GA)" or "macular degeneration"). No language restriction was applied for searching and study inclusion, and we assessed the reference lists of retrieved articles and relevant reviews for additional published and unpublished data. When datasets were incomplete for the required data, corresponding authors were contacted for additional information.
Study selection.
Articles that met all of the following criteria were included: 1) cohort studies, case-control or cross-sectional were published as an original article; although randomized clinical trials (RCTs) would have been considered, no trials were available; 2) the study objective was to evaluate the relationship between stain use and AMD; 3) the definition of AMD had to be clearly stated; and 4) studies were also required to present the relative risks (RRs) or odds ratios (ORs) or hazard ratios (HRs) with their 95% confidence interval (CI) or sufficient data to calculate these. When multiple publications reported on the same or overlapping data, we only included the publication with the most subjects. According to the sample size and different stages of AMD, the BMES by Tan et al. independently assessed the retrieved studies. Any inconsistencies were resolved through consensus with a third author (L. M.) for adjudication.
Data extraction and quality assessment. We extracted the following information from the eligible studies:
first author, year of publication, study design, number of subjects, average age, sex distribution, diagnosis method, classification criteria, type of macular degeneration, the RRs (ORs or HRs) overall and in each subgroup and the corresponding CI, and the confounding factors were matched or adjusted in the studies. When a study provided several risk estimates, the most completely adjusted estimate was extracted.
Because no available RCTs were intensified, the Quality of Reporting of Meta-analyses guidelines is not directly appropriate 37 . Therefore, we conformed to the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines. The studies were categorized as good quality when at least half of the criteria were clearly described and accounted for, as studies that met less than half criteria were considered fair quality or poor quality 38 . Three authors (Y.-F. W., J.-H. D. and R. Z.) independently extracted data and assessed study quality; and any discrepancies were resolved through discussion.
Outcome measurement. The definition of AMD varied between studies using International Classification and Grading System (ICGS) and Wisconsin Age-related Maculopathy Grading System (WARMGS). Briefly, early AMD (grades 2 and 3) was defined as the appearance of indistinct soft/reticular drusen or large distinct soft drusen (≥ 125 μ m in diameter). Late AMD was defined as presence of either CNV or GA. Any AMD was defined in participants as the appearance at early or late AMD. For studies reporting results separately in early and late stages, the risk estimates were pooled as any AMD prior to the inclusion of the study in the overall analysis.
Statistical analysis. The measure of effect of interest is the RR with 95% CI which is an intuitive and commonly used measure in the medical and public health literature. Because AMD is not common, ORs, HRs or RRs could be considered an approximation of relative risk. The associations between statin use and the risk of AMD were estimated after calculating pooled RRs and 95% CI, using a fixed effects model or a random effects model according to the heterogeneity. Heterogeneity among individual studies was evaluated by calculating the Cochran's Q statistic and the I 2 test (P < 0.10 indicates an existence of heterogeneity and I 2 > 50% indicated a statistical significance). We performed a meta-analysis using all observational studies; and only cohort and case-control studies were identified and included in the secondary analysis to be discussed later. In case of significant heterogeneity, the sources of heterogeneity were explored were performed. The variables included in the subgroup analyses were study type (Cohort v. Case-control v. Cross-sectional), region of origin (America v. Europe v. Australia v. Asian), mean age of participants (≥ 65 v.< 65 years), classification criteria of AMD (WARMGS v. ICGS v. ICGS and WARMGS) and study quality (Good v. Fair). In addition, sensitivity analyses, by sequentially removing one study at a time, were performed to evaluate whether the results could have been affected markedly by a single study. To assess for publication biases, the Begg's test, the Egger's test and funnel plots were evaluated 39, 40 . We used STATA version 11.0 (Stata Corp LP, College Station, TX) for all statistical analyses. Two-sided P values less than 0.05 were considered statistically significant, except for tests of heterogeneity, Egger's linear regression and Begg's rank correlation, where a level of 0.10 was used.
